Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001206520 | SCV001377831 | pathogenic | Glycogen storage disorder due to hepatic glycogen synthase deficiency | 2019-09-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Phe155Leufs*4) in the GYS2 gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs763929651, ExAC 0.002%). This variant has not been reported in the literature in individuals with GYS2-related conditions. Loss-of-function variants in GYS2 are known to be pathogenic (PMID: 9691087). For these reasons, this variant has been classified as Pathogenic. |
3billion | RCV001206520 | SCV003841995 | pathogenic | Glycogen storage disorder due to hepatic glycogen synthase deficiency | 2023-02-23 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). This variant was predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported to be associated with GYS2 related disorder (ClinVar ID: VCV000937499). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. |